Information Provided By:
Fly News Breaks for September 13, 2017
GHDX
Sep 13, 2017 | 05:48 EDT
Genomic Health and Biocartis Group NV announced an exclusive agreement to develop an in vitro diagnostic, or IVD, version of the Oncotype DX Breast Recurrence Score test on Biocartis' Idylla platform that can be performed locally by laboratory partners and in hospitals around the world. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient's breast tumor tissue to provide personalized information for tailoring treatment based on the biology of their individual disease. As the only test proven to predict chemotherapy benefit, the Oncotype DX Breast Recurrence Score test is included in all major cancer guidelines worldwide and is now considered standard of care for early-stage breast cancer.
News For GHDX From the Last 2 Days
There are no results for your query GHDX